Navigation Links
Varian, Inc. Reports Fourth Quarter 2009 Results
Date:11/4/2009

PALO ALTO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Varian, Inc. (NasdaqGS: VARI) today reported fourth quarter fiscal year 2009 revenues of $196.5 million, a decrease of 30.4% from the fourth quarter of fiscal year 2008. Orders exceeded revenues by approximately $9 million in the fourth quarter of fiscal year 2009.

Non-GAAP (adjusted) diluted earnings per share for the fourth quarter of 2009 were $0.40, a decrease of 48.7% from the $0.78 in the fourth quarter of 2008. On a GAAP basis, diluted earnings per share in the fourth quarter of 2009 were $0.07 (including $0.28 of costs relating to the pending acquisition of the company by Agilent Technologies, Inc. ("Agilent")), compared to $0.69 in the fourth quarter of 2008.

Adjusted operating profit margin was 8.4% in the fourth quarter of 2009, compared to 13.0% in the prior-year quarter. On a GAAP basis, operating profit margin was 2.6% in the fourth quarter of 2009, compared to 11.6% in the same quarter a year ago.

Revenues in the fourth quarter of fiscal year 2009 were essentially flat on a sequential basis, but were lower than the prior-year quarter, primarily due to the global economic downturn as well as specific items impacting the comparability of the fourth quarter of fiscal year 2009 with the fourth quarter of fiscal year 2008. Revenues in the fourth quarter of fiscal year 2008 benefitted from (1) an extra week and (2) exceptionally strong shipments related to overcoming manufacturing transition and execution issues experienced in the third quarter of fiscal year 2008. In addition, revenues in the fourth quarter of fiscal year 2009 were negatively impacted by customers' uncertainty and other disruptions related to the announcement and pendency of the acquisition by Agilent. Compared to record adjusted operating profit margins in the prior-year quarter, adjusted operating margins in the fourth quarter of fiscal year 2009 were negatively impacted by the lower sale
'/>"/>

SOURCE Varian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Fujirebio Diagnostics Inc., a Malvern-based ... the Year by the Eastern Technology Council at ... in Philadelphia on Thursday, December 3, 2009. ... Philadelphia region,s largest technology and life sciences trade ... Technology and Life Sciences Community, the awards are ...
(Date:12/14/2009)... Calif., Dec. 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... AZ-004 is an inhalation product candidate being developed for ... or bipolar disorder. The IND for Staccato ... 2005. ,, "AZ-004 has delivered a predictable and consistent ...
(Date:12/14/2009)... Zargis Medical Corp., a majority-owned subsidiary ... a spin-off from Siemens Corporate Research (NYSE: ... begun selling its award-winning Zargis Cardioscan(TM) system on ... its accompanying Bluetooth®-enabled electronic stethoscope were jointly named ... Innovation of the Year." Cardioscan is the ...
Breaking Medicine Technology:Fujirebio Diagnostics Named Life Sciences Company of the Year 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2MHA Announces Gloria Barr Esq as Vice President 26 General Counsel 54636 1MHA Announces Gloria Barr Esq as Vice President 26 General Counsel 54636 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 1Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 3Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 4Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K 12 54633 1Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K 12 54633 2Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K 12 54633 3
... Cardium Therapeutics,(Amex: CXM ) and ... that,positive findings from a preclinical study, demonstrating ... hyperthermia (cooling) for the potential,treatment of acute ... by BioMed Central (BMC) Cardiovascular Disorders (2008, ...
... Assess Feasibility of Dose-sparing and ... Vaccination Against H5N1 Flu -, GAITHERSBURG, Md., April 15 ... has received approval from the,Department of Health and Human Services ... for use with an injected H5N1,influenza vaccine. This decision was ...
Other Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch 2Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch 3Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch 4
(Date:12/14/2009)... Heska Corporation (Nasdaq: HSKA ; "Heska" ... veterinary diagnostic and specialty products, today announced ... new DRI-CHEM® 7000 Veterinary Chemistry Analyzer (the ... ,, Customers receiving these analyzers have invested ... available to the veterinary in-clinic market. ...
(Date:12/14/2009)... National Organization for Rare Disorders (NORD) today called upon ... annual health insurance caps. In a full-page ad ... on Capitol Hill, NORD said the current Senate health ... continue for most Americans, contrary to what many people ... welcomes the promises made by President Obama and Congress ...
(Date:12/14/2009)... say , , MONDAY, Dec. 14 (HealthDay News) -- U.S. ... single gene linked to heart failure. , The team ... analyzed the DNA of a large group of white ... four genes that could be connected with heart failure. ... 625 healthy whites led the researchers to identify 12 ...
(Date:12/14/2009)... , ... La Jolla, Calif. (Vocus) -- The physicians at ... the new chief of staff of the 372-bed facility. Dr. Sedwitz ... Jan. 1, 2010. , , , , ,During his two-year term, ... Jolla’s administrative staff and its board of directors. Dr. Sedwitz will ...
(Date:12/14/2009)... Pasierb, President ,, NEW YORK, Dec. 14 ... the Future study (MTF) -- the largest survey on ... 12th graders -- underscores that teens, intentional abuse of ... a cause for concern, with an alarming number of ... relatives. ,, Teen Abuse of Medication ...
Breaking Medicine News(10 mins):Health News:Heska Announces Installation of New Chemistry Analyzer 2Health News:Heska Announces Installation of New Chemistry Analyzer 3Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3
... have carried out the world's first successful heart surgery to ... operation was performed at Siriraj Hospital on February 20 by ... than 50 days later the separated twins were still in ... the world that doctors have successfully separated Siamese twins joined ...
... been accused of being institutionally racist. In this week’s ... pioneers in moving towards equity, they have some way ... multi-cultural society. ,The "Count me in" census, ... reading for people of African and Caribbean origin living ...
... of prostate-specific antigen (PSA) in a man’s bloodstream at ... rate of change over the course of the disease// ... a study in the April 4 Journal of the ... localized prostate cancer have high long-term survival rates, many ...
... epidemic, a leading obstetricians has warned//. ,"Any ... With Caesarean this is the risk if the procedure is ... former Director of the Dublin-based National Maternity Hospital, which is ... ,Speaking at a seminar in New Delhi, he said ...
... closer to menopause tend to have a reduced risk ... treatment// further from menopause, according to a study. ... postmenopausal hormone therapy on coronary heart disease (CHD) have ... conducted. There may be a number of reasons for ...
... leading organization of conscientious and concerned doctors, has issued an ... has brought against India, demanding a patent for one of ... drug firms have a habit of making minor improvements in ... ,India has been saying the products are not new ...
Other Medicine News:Health News:Chances of Tackling Racism in Mental Health Care is Still Remote 2Health News:PSA Not a Good Predictor of Lethal Prostate Cancer 2Health News:'Alarming Rise in Caesarean Births a Cause of Concern' 2Health News:Starting Time of Hormone Therapy may Augment the Risk of Coronary Heart Disease 2Health News:People Before Patents 2
... B6 makes it possible to determine the,vitamin ... method. The kits includes all reagents in,ready ... of the samples with,exception of the columns. ... simultaneous handling of many analytes in a ...
ELISA kit for the quantitative determination of autoantibodies to tissue transglutaminase (tTG) in serum....
... Increased volume for use with 4, 8, or ... permits withdrawal of nearly all of the solution. ... solution. Made of natural virgin polystyrene containing no ... Sterilized by irradiation. Dimensions: 78 mm W x ...
Volume: 25 ml; Volume Graduation: 2/10 ml...
Medicine Products: